ciglitazone has been researched along with Demyelinating Diseases in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raikwar, HP | 1 |
| Muthian, G | 1 |
| Rajasingh, J | 1 |
| Johnson, CN | 1 |
| Bright, JJ | 1 |
1 other study available for ciglitazone and Demyelinating Diseases
| Article | Year |
|---|---|
PPARgamma antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-deoxy-Delta12,14-prostaglandin J2.
Topics: Animals; Antigens; Benzamides; Benzhydryl Compounds; Cell Differentiation; Cell Proliferation; Demye | 2006 |